Clinical Trial Update: An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease [Phase 2]

View source ↗

Summary

The extension Phase 2 study of Minzasolmin (UCB0599) in Parkinson's disease has been terminated, with long-term efficacy, safety and tolerability results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Minzasolmin (UCB0599)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Parkinson's Disease | Phase 2 | Status: TERMINATED | Results posted: 2026-04-02